Clinical coagulation laboratories use a variety of reagents and methods to assay protein C function and antigen. The purpose of this study was to evaluate the performance of these various methods and to gauge the relative frequency with which each is used.
Results:
The most common reagents for protein C antigen were Stago (35%), Corgenix (28%) and Helena Laboratories (17%); for protein C function (chromogenic) the most common were Chromogenix/IL (33%), Stago (25%), Precision Biologic (17%) and Siemens (17%) and for protein C function (clot-based) the most common were Siemens (38%), Precision Biologic (25%) and Stago (25%). For the first survey, the mean protein C result was 26% antigen, 24% chromogenic function and 29% clot function. All 46 laboratories (73 independent observations) correctly identified this sample as abnormal and the differences in levels as measured by various ELISA assays (inter-group range 22-28%), chromogenic assays (inter-group range 22-26%) and clot-based assays (inter-group range 21-31%) were not clinically significant. The number of laboratories using immunodiffusion or immuno-electrophoresis assays (inter-group range 34-47%) was small, but nevertheless these methods provided somewhat higher antigenic results than the ELISA assays (mean ELISA 24%, immuno methods=42%; p<0.05, Student's t-test, two-tails, unequal variance). Similarly, for the second survey, (mean results 21%, 23% and 24% by antigen, chromogenic and clot-based methods, respectively), and the third survey (mean results 46%, 49% and 50% by antigen, chromogenic and clot-based methods, respectively), no clear clinically significant biases between groups emerged, and all results were correctly classified as abnormal except for a very small number in the third survey, which evaluated a sample with a higher protein C level. For protein C antigen ELISA, inter-lab CV was as follows: Corgenix (35%, 24%, 12%, for surveys 1,2 and 3, respectively), Helena Laboratories (16%, 12% and 16%), and Stago (14%, 17%, 16%). For chromogenic function, CV estimates were Chromogenix/IL (13%, 12%, 4% across multiple manufacturer's analyzer platforms), Precision Biologic (3%, 17%, 8% across multiple manufacturer's analyzer platforms), Siemens (18%, 12%, 4% across a single analyzer platform), and Stago (6%, 3%, 5% across multiple analyzer platforms from the same manufacturer). For clot-based function, CV estimates were Precision Biologic (16%, 23%, 12% across multiple manufacturer's analyzer platforms), Siemens (11%, 14%, 6% across multiple manufacturer's analyzer platforms), and Stago (17%, 8%, 11% across multiple analyzer platforms from the same manufacturer). These CV values are across laboratories and in most cases across analyzer platforms; estimates for intralaboratory CV would be expected to be considerably lower.
Conclusions:
We conclude that, although certain immune-diffusion or immuno-electrophoresis methods tended to run higher than other methods, all methods performed acceptably well in detecting low protein C and that most variation among different methods is likely to be clinically insignificant.
